ObesityGLP1 agonists: FDA investigates suicide riskLatest NewsFollowing in the footsteps of the European Medicines Agency (EMA), the US FDA is now also investigating the side effects of obesity blockbusters. Read more 5 January 2024 https://european-biotechnology.com/wp-content/uploads/2024/04/FDA_Bldg_31_-_Exterior__5161375422_-scaled.jpeg 2560 1706 Thomas Gabrielczyk /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Thomas Gabrielczyk2024-01-05 15:25:312024-07-09 12:33:07GLP1 agonists: FDA investigates suicide risk